A Phase 2/3 interventional study of 18F-DCFPyL Injection and PET/CT imaging in Prostate Cancer, sponsored by Progenics Pharmaceuticals, Inc.. Completed at 10 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-09.
Sponsored by Progenics Pharmaceuticals, Inc. (part of Lantheus Holdings, Inc.) · Phase 2/3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing piflufolastat in Prostatic Neoplasms — 5 open to participants now, 9 under way, none of them phase 3. piflufolastat · Prostatic Neoplasms.
Among the 24 studies testing piflufolastat in Prostatic Neoplasms, this one has the largest enrollment, is one of 3 that started in 2016, is one of 3 in phase 2/3, and was the 4th registered.
7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.
Browse Prostatic Neoplasms studies →5 of the 24 studies testing piflufolastat in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Akiva Mintz · Sites in United States
Ages 18–120 · Healthy volunteers
OHSU Knight Cancer Institute · Sites in United States
Ages 18+ · Men only
Brigham and Women's Hospital · Sites in United States
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18–100 · Men only
National Cancer Institute (NCI) · Sites in United States
Ages 18–120 · Men only
By country, each count listing its studies:
piflufolastat: first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 4 · Phase 4 5
First in 2014; this study’s year is marked. 3 started in 2016.
This study's enrollment of 385 is above the median of 60 across 5,353 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 55 across the 24 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Progenics Pharmaceuticals, Inc., one of the names counted as Lantheus Holdings, Inc.. Under that name alone:
Progenics Pharmaceuticals, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
22 studies in Prostatic Neoplasms by Lantheus Holdings, Inc.: 1 open now, 2 under way, 1 of them phase 3. Of 19 finished, 6 (32%) have results posted.
Among the 22 studies in Prostatic Neoplasms by Lantheus Holdings, Inc., this one is the 3rd largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2016, is one of 2 in phase 2/3, and was the 17th registered.
Lantheus Holdings, Inc.’s Prostatic Neoplasms studies by the year they started, since 2008.
1 of the studies testing piflufolastat in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06099093Brigham and Women's HospitalPilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies testing piflufolastat in Prostatic Neoplasms, from their registry updates:
Among Lantheus Holdings, Inc.’s 22 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy (Cohort A) or in patients with locally recurrent or metastatic disease willing to undergo biopsy (Cohort B).
Cohort B is complete and no longer recruiting subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cohort A Only:
Cohort B Only: [Enrollment is complete; No longer recruiting subjects]
Exclusion Criteria:
Cohort A Only:
Cohort B Only: [Enrollment is Complete; No longer recruiting subjects]
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
Drug: 18F-DCFPyL Injection · Diagnostic Test: PET/CT imaging
A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
Also known as: PyL
PET/CT imaging will be acquired 1-2 hours post-PyL injection
Specificity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A)
The primary analysis in Cohort A will test the co-primary endpoints of sensitivity and specificity of 18F-DCFPyL PET/CT imaging relative to histopathology for metastatic disease in pre-prostatectomy patients. For each co-primary endpoint there will be three independent imaging readers. At least two of the three readers must reject the null hypothesis for specificity to be deemed a success. If specificity is a success, then the same two readers need to reject the null hypothesis for sensitivity to reach overall success of the primary endpoint.
Time frame: Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
Sensitivity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A)
The primary analysis in Cohort A will test the co-primary endpoints of sensitivity and specificity of 18F-DCFPyL PET/CT imaging relative to histopathology for metastatic disease in pre-prostatectomy patients. For each co-primary endpoint there will be three independent imaging readers. At least two of the three readers must reject the null hypothesis for specificity to be deemed a success. If specificity is a success, then the same two readers need to reject the null hypothesis for sensitivity to reach overall success of the primary endpoint.
Time frame: Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
Shift From Baseline in Selected Hematology Laboratory Values at Follow-up (Safety Outcome Measure)
Shifts from baseline to worst post-baseline visit for hematology laboratory values for all participants included in the Safety Set. The Safety Set includes all participants who received any amount of 18F-DCFPyL. Data are presented for participants in Cohort A and Cohort B.
Time frame: From time of screening (baseline) until pre-surgery/biopsy (within 28 days post-study drug dosing).
Shift From Baseline in Selected Clinical Chemistry Laboratory Values at Follow-up (Safety Outcome Measure)
Shifts from baseline to worst post-baseline visit for clinical chemistry laboratory values for all participants included in the Safety Set. The Safety Set includes all participants who received any amount of 18F-DCFPyL. Data are presented for participants in Cohort A and Cohort B.
Time frame: From time of screening (baseline) until pre-surgery/biopsy (within 28 days post-study drug dosing).
Changes From Baseline in Electrocardiogram (ECG) Parameters (Safety Outcome Measure)
Time frame: Changes in ECG pre-drug dosing and within 1-2 hours post-dosing
Mean Changes From Baseline in Blood Pressure Post 18F-DCFPyL Dosing (Safety Outcome Measure)
Time frame: Measured at two intervals on the day of dosing, pre-dosing (baseline) and post-dosing/pre-imaging.
Mean Change From Baseline in Heart Rate Post 18F-DCFPyL Dosing (Safety Outcome Measure)
Time frame: Measured at two intervals on the day of dosing, pre-dosing (baseline) and post-dosing/pre-imaging.
Mean Change From Baseline in Respiration Rate Post 18F-DCFPyL Dosing (Safety Outcome Measure)
Time frame: Measured at two intervals on the day of dosing, pre-dosing (baseline) and post-dosing/pre-imaging.
Mean Change From Baseline in Temperature Post 18F-DCFPyL Dosing (Safety Outcome Measure)
Time frame: Measured at two intervals on the day of dosing, pre-dosing (baseline) and post-dosing/pre-imaging.
Sensitivity of 18F-DCFPyL PET/CT Imaging to Detect Prostate Cancer Within Sites of Metastasis or Local Recurrence Relative to Histopathology in Participants With Recurrent or Metastatic Prostate Cancer (Cohort B)
Sensitivity (True Positive rate) measures the proportion of positives that are correctly identified (i.e., the proportion of those who have some condition (affected) who are correctly identified as having the condition).
Time frame: Within 28 days of 18F-DCFPyL PET/CT imaging, conventional image-guided biopsy occurred.
Comparison of Detection Rates for Lesion Counts By Location and Overall Between 18F-DCFPyL PET/CT and Conventional Imaging
The number of lesions detected on imaging categorized as bone, visceral/soft tissue, lymph nodes, and the prostate gland will be determined by each of the central imaging core lab independent readers. The sum of lesions per participant per tissue type and overall will be computed for each participant based on each reader's lesion count. This will be calculated from the 18F-DCFPyL PET/CT scan results as well as the conventional imaging results.
Time frame: Within 1-2 hours of 18F-DCFPyL dosing, a whole body PET/CT scan will be taken
Positive Predictive Value (PPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Prostate Gland of High Risk Prostate Cancer Participants (Cohort A)
Positive Predictive Value (PPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The PPV is determined from the number of true positives (positive 18F-DCFPyL image and a positive histopathology result for prostate cancer) divided by the number of participants with a positive 18F-DCFPyL image.
Time frame: Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
Negative Predictive Value (NPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Prostate Gland of High Risk Prostate Cancer Participants (Cohort A)
Negative Predictive Value (NPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The NPV is determined from the number of true negatives (negative 18F-DCFPyL image and a negative histopathology result for prostate cancer) divided by the number of participants with a negative 18F-DCFPyL image.
Time frame: Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
Positive Predictive Value (PPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Lymph Nodes of High Risk Prostate Cancer Participants (Cohort A)
Positive Predictive Value (PPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The PPV is determined from the number of true positives (positive 18F-DCFPyL image and a positive histopathology result for prostate cancer) divided by the number of participants with a positive 18F-DCFPyL image.
Time frame: Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
Negative Predictive Value (NPV) of 18F-DCFPyL PET/CT to Predict Prostate Cancer Within the Lymph Nodes of High Risk Prostate Cancer Participants (Cohort A)
Negative Predictive Value (NPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The NPV is determined from the number of true negatives (negative 18F-DCFPyL image and a negative histopathology result for prostate cancer) divided by the number of participants with a negative 18F-DCFPyL image.
Time frame: Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
Positive Predictive Value (PPV) of 18F-DCFPyL PET/CT Imaging to Predict Prostate Cancer Within Sites of Local Recurrence and Other Metastatic Lesions in Participants With Recurrent or Metastatic Prostate Cancer (Cohort B)
Positive Predictive Value (PPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The PPV is determined from the number of true positives (positive 18F-DCFPyL image and a positive histopathology result for prostate cancer) divided by the number of participants with a positive 18F-DCFPyL PET/CT image.
Time frame: Within 28 days of 18F-DCFPyL PET/CT imaging, conventional image-guided biopsy will occur.
Peak Plasma Concentration (Cmax) of 18F-DCFPyL in a Subset of Participants
Time frame: Samples were collected at 0, 5, 15, 30, 60, 120, 240, 360, and 480 minutes after administration of 18F-DCFPyL.
Area Under the Plasma Concentration Versus Time Curve (AUC) of 18F-DCFPyL in a Subset of Participants
Time frame: Samples were collected at 0, 5, 15, 30, 60, 120, 240, 360, and 480 minutes after administration of 18F-DCFPyL.
| Milestone | High Risk Prostate Cancer (Cohort A) | Recurrent or Metastatic Prostate Cancer (Cohort B) |
|---|---|---|
| Started | 268 | 117 |
| Completed | 248 | 102 |
| Not completed | 20 | 15 |
The primary analysis in Cohort A will test the co-primary endpoints of sensitivity and specificity of 18F-DCFPyL PET/CT imaging relative to histopathology for metastatic disease in pre-prostatectomy patients. For each co-primary endpoint there will be three independent imaging readers. At least two of the three readers must reject the null hypothesis for specificity to be deemed a success. If specificity is a success, then the same two readers need to reject the null hypothesis for sensitivity to reach overall success of the primary endpoint.
| percentage of participants | High Risk Prostate Cancer (Cohort A) |
|---|---|
| Central Reader 1 | 97.9 (94.52 to 99.37) |
| Central Reader 2 | 98.9 (96.00 to 99.96) |
| Central Reader 3 | 96.3 (93.64 to 98.99) |
The primary analysis in Cohort A will test the co-primary endpoints of sensitivity and specificity of 18F-DCFPyL PET/CT imaging relative to histopathology for metastatic disease in pre-prostatectomy patients. For each co-primary endpoint there will be three independent imaging readers. At least two of the three readers must reject the null hypothesis for specificity to be deemed a success. If specificity is a success, then the same two readers need to reject the null hypothesis for sensitivity to reach overall success of the primary endpoint.
| percentage of participants | High Risk Prostate Cancer (Cohort A) |
|---|---|
| Central Reader 1 | 41.9 (29.65 to 54.22) |
| Central Reader 2 | 30.6 (19.17 to 42.12) |
| Central Reader 3 | 40.3 (28.11 to 52.53) |
Shifts from baseline to worst post-baseline visit for hematology laboratory values for all participants included in the Safety Set. The Safety Set includes all participants who received any amount of 18F-DCFPyL. Data are presented for participants in Cohort A and Cohort B.
| Participants | Cohort A - Follow-up Value: Low | Cohort B - Follow-up Value: Low | Cohort A - Follow-up Value: Normal | Cohort B - Follow-up Value Normal | Cohort A - Follow-up Value: High | Cohort B - Follow-up Value: High | Cohort A - Follow-up Value: Missing | Cohort B - Follow-up Value: Missing |
|---|---|---|---|---|---|---|---|---|
| Hematocrit — Cohort A - Baseline Value: Low | 26 | 0 | 12 | 0 | 0 | 0 | 2 | 0 |
| Hematocrit — Cohort B - Baseline Value: Low | 0 | 31 | 0 | 6 | 0 | 0 | 0 | 10 |
| Hematocrit — Cohort A - Baseline Value: Normal | 29 | 0 | 179 | 0 | 1 | 0 | 12 | 0 |
| Hematocrit — Cohort B - Baseline Value: Normal | 0 | 1 | 0 | 47 | 0 | 0 | 0 | 22 |
| Hematocrit — Cohort A - Baseline Value: High | 0 | 0 | 4 | 0 | 1 | 0 | 0 | 0 |
| Hematocrit — Cohort B - Baseline Value: High | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematocrit — Cohort A - Baseline Value: Missing | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Hematocrit — Cohort B - Baseline Value: Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin — Cohort A - Baseline Value: Low | 16 | 0 | 3 | 0 | 0 | 0 | 2 | 0 |
| Hemoglobin — Cohort B - Baseline Value: Low | 0 | 33 | 0 | 6 | 0 | 0 | 0 | 13 |
| Hemoglobin — Cohort A - Baseline Value: Normal | 18 | 0 | 210 | 0 | 1 | 0 | 11 | 0 |
| Hemoglobin — Cohort B - Baseline Value: Normal | 0 | 2 | 0 | 43 | 0 | 0 | 0 | 18 |
| Hemoglobin — Cohort A - Baseline Value: High | 0 | 0 | 3 | 0 | 1 | 0 | 1 | 0 |
| Hemoglobin — Cohort B - Baseline Value: High | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Hemoglobin — Cohort A - Baseline Value: Missing | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin — Cohort B - Baseline Value: Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets — Cohort A - Baseline Value: Low | 12 | 0 | 3 | 0 | 0 | 0 | 1 | 0 |
| Platelets — Cohort B - Baseline Value: Low | 0 | 9 | 0 | 2 | 0 | 0 | 0 | 3 |
| Platelets — Cohort A - Baseline Value: Normal | 4 | 0 | 230 | 0 | 1 | 0 | 13 | 0 |
| Platelets — Cohort B - Baseline Value: Normal | 0 | 3 | 0 | 70 | 0 | 0 | 0 | 29 |
| Platelets — Cohort A - Baseline Value: High | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Platelets — Cohort B - Baseline Value: High | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Platelets — Cohort A - Baseline Value: Missing | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Platelets — Cohort B - Baseline Value: Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Erythrocytes — Cohort A - Baseline Value: Low | 29 | 0 | 8 | 0 | 0 | 0 | 2 | 0 |
| Erythrocytes — Cohort B - Baseline Value: Low | 0 | 36 | 0 | 1 | 0 | 0 | 0 | 10 |
| Erythrocytes — Cohort A - Baseline Value: Normal | 20 | 0 | 194 | 0 | 0 | 0 | 11 | 0 |
| Erythrocytes — Cohort B - Baseline Value: Normal | 0 | 6 | 0 | 39 | 0 | 0 | 0 | 22 |
| Erythrocytes — Cohort A - Baseline Value: High | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Erythrocytes — Cohort B - Baseline Value: High | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 |
| Erythrocytes — Cohort A - Baseline Value: Missing | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Erythrocytes — Cohort B - Baseline Value: Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytes — Cohort A - Baseline Value: Low | 7 | 0 | 3 | 0 | 0 | 0 | 2 | 0 |
| Leukocytes — Cohort B - Baseline Value: Low | 0 | 7 | 0 | 1 | 0 | 0 | 0 | 2 |
| Leukocytes — Cohort A - Baseline Value: Normal | 4 | 0 | 208 | 0 | 18 | 0 | 12 | 0 |
| Leukocytes — Cohort B - Baseline Value: Normal | 0 | 0 | 0 | 71 | 0 | 1 | 0 | 30 |
| Leukocytes — Cohort A - Baseline Value: High | 0 | 0 | 7 | 0 | 5 | 0 | 0 | 0 |
| Leukocytes — Cohort B - Baseline Value: High | 0 | 0 | 0 | 3 | 0 | 2 | 0 | 0 |
| Leukocytes — Cohort A - Baseline Value: Missing | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Leukocytes — Cohort B - Baseline Value: Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shifts from baseline to worst post-baseline visit for clinical chemistry laboratory values for all participants included in the Safety Set. The Safety Set includes all participants who received any amount of 18F-DCFPyL. Data are presented for participants in Cohort A and Cohort B.
| Participants | Cohort A - Follow-up Value: Low | Cohort B - Follow-up Value: Low | Cohort A - Follow-up Value: Normal | Cohort B - Follow-up Value: Normal | Cohort A - Follow-up Value: High | Cohort B - Follow-up Value: High | Cohort A - Follow-up Value: Missing | Cohort B - Follow-up Value: Missing |
|---|---|---|---|---|---|---|---|---|
| Alkaline Phosphatase — Cohort A - Baseline Value: Low | 3 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Alkaline Phosphatase — Cohort B - Baseline Value: Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Alkaline Phosphatase — Cohort A - Baseline Value: Normal | 5 | 0 | 210 | 0 | 0 | 0 | 38 | 0 |
| Alkaline Phosphatase — Cohort B - Baseline Value: Normal | 0 | 0 | 0 | 61 | 0 | 4 | 0 | 35 |
| Alkaline Phosphatase — Cohort A - Baseline Value: High | 0 | 0 | 4 | 0 | 3 | 0 | 0 | 0 |
| Alkaline Phosphatase — Cohort B - Baseline Value: High | 0 | 0 | 0 | 0 | 0 | 9 | 0 | 4 |
| Alkaline Phosphatase — Cohort A - Baseline Value: Missing | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Alkaline Phosphatase — Cohort B - Baseline Value: Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alanine Aminotransferase — Cohort A - Baseline Value: Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alanine Aminotransferase — Cohort B - Baseline Value: Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alanine Aminotransferase — Cohort A - Baseline Value: Normal | 0 | 0 | 197 | 0 | 7 | 0 | 35 | 0 |
| Alanine Aminotransferase — Cohort B - Baseline Value: Normal | 0 | 1 | 0 | 67 | 0 | 2 | 0 | 42 |
| Alanine Aminotransferase — Cohort A - Baseline Value: High | 0 | 0 | 9 | 0 | 14 | 0 | 4 | 0 |
| Alanine Aminotransferase — Cohort B - Baseline Value: High | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 1 |
| Alanine Aminotransferase — Cohort A - Baseline Value: Missing | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Alanine Aminotransferase — Cohort B - Baseline Value: Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Aspartate Aminotransferase — Cohort A - Baseline Value: Low | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Aspartate Aminotransferase — Cohort B - Baseline Value: Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Aspartate Aminotransferase — Cohort A - Baseline Value: Normal | 8 | 0 | 193 | 0 | 4 | 0 | 43 | 0 |
| Aspartate Aminotransferase — Cohort B - Baseline Value: Normal | 0 | 0 | 0 | 60 | 0 | 4 | 0 | 45 |
| Aspartate Aminotransferase — Cohort A - Baseline Value: High | 0 | 0 | 4 | 0 | 8 | 0 | 1 | 0 |
| Aspartate Aminotransferase — Cohort B - Baseline Value: High | 0 | 0 | 0 | 1 | 0 | 5 | 0 | 1 |
| Aspartate Aminotransferase — Cohort A - Baseline Value: Missing | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 |
| Aspartate Aminotransferase — Cohort B - Baseline Value: Missing | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Bilirubin — Cohort A - Baseline Value: Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin — Cohort B - Baseline Value: Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin — Cohort A - Baseline Value: Normal | 1 | 0 | 194 | 0 | 22 | 0 | 33 | 0 |
| Bilirubin — Cohort B - Baseline Value: Normal | 0 | 0 | 0 | 69 | 0 | 2 | 0 | 41 |
| Bilirubin — Cohort A - Baseline Value: High | 0 | 0 | 5 | 0 | 6 | 0 | 5 | 0 |
| Bilirubin — Cohort B - Baseline Value: High | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 2 |
| Bilirubin — Cohort A - Baseline Value: Missing | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Bilirubin — Cohort B - Baseline Value: Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium — Cohort A - Baseline Value: Low | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium — Cohort B - Baseline Value: Low | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Calcium — Cohort A - Baseline Value: Normal | 25 | 0 | 219 | 0 | 0 | 0 | 18 | 0 |
| Calcium — Cohort B - Baseline Value: Normal | 0 | 1 | 0 | 81 | 0 | 0 | 0 | 32 |
| Calcium — Cohort A - Baseline Value: High | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 |
| Calcium — Cohort B - Baseline Value: High | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Calcium — Cohort A - Baseline Value: Missing | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Calcium — Cohort B - Baseline Value: Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine — Cohort A - Baseline Value: Low | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Creatinine — Cohort B - Baseline Value: Low | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 0 |
| Creatinine — Cohort A - Baseline Value: Normal | 1 | 0 | 223 | 0 | 9 | 0 | 15 | 0 |
| Creatinine — Cohort B - Baseline Value: Normal | 0 | 2 | 0 | 66 | 0 | 2 | 0 | 32 |
| Creatinine — Cohort A - Baseline Value: High | 0 | 0 | 4 | 0 | 8 | 0 | 0 | 0 |
| Creatinine — Cohort B - Baseline Value: High | 0 | 0 | 0 | 3 | 0 | 6 | 0 | 1 |
| Creatinine — Cohort A - Baseline Value: Missing | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 0 |
| Creatinine — Cohort B - Baseline Value: Missing | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Glucose — Cohort A - Baseline Value: Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose — Cohort B - Baseline Value: Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose — Cohort A - Baseline Value: Normal | 0 | 0 | 155 | 0 | 19 | 0 | 9 | 0 |
| Glucose — Cohort B - Baseline Value: Normal | 0 | 2 | 0 | 25 | 0 | 14 | 0 | 16 |
| Glucose — Cohort A - Baseline Value: High | 0 | 0 | 20 | 0 | 53 | 0 | 7 | 0 |
| Glucose — Cohort B - Baseline Value: High | 0 | 0 | 0 | 13 | 0 | 29 | 0 | 17 |
| Glucose — Cohort A - Baseline Value: Missing | 0 | 0 | 3 | 0 | 1 | 0 | 1 | 0 |
| Glucose — Cohort B - Baseline Value: Missing | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Potassium — Cohort A - Baseline Value: Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium — Cohort B - Baseline Value: Low | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Potassium — Cohort A - Baseline Value: Normal | 5 | 0 | 226 | 0 | 7 | 0 | 18 | 0 |
| Potassium — Cohort B - Baseline Value: Normal | 0 | 2 | 0 | 75 | 0 | 0 | 0 | 35 |
| Potassium — Cohort A - Baseline Value: High | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 0 |
| Potassium — Cohort B - Baseline Value: High | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 |
| Potassium — Cohort A - Baseline Value: Missing | 0 | 0 | 4 | 0 | 0 | 0 | 1 | 0 |
| Potassium — Cohort B - Baseline Value: Missing | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Urea Nitrogen — Cohort A - Baseline Value: Low | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urea Nitrogen — Cohort B - Baseline Value: Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urea Nitrogen — Cohort A - Baseline Value: Normal | 1 | 0 | 222 | 0 | 8 | 0 | 12 | 0 |
| Urea Nitrogen — Cohort B - Baseline Value: Normal | 0 | 0 | 0 | 54 | 0 | 8 | 0 | 25 |
| Urea Nitrogen — Cohort A - Baseline Value: High | 0 | 0 | 11 | 0 | 7 | 0 | 2 | 0 |
| Urea Nitrogen — Cohort B - Baseline Value: High | 0 | 0 | 0 | 4 | 0 | 16 | 0 | 10 |
| Urea Nitrogen — Cohort A - Baseline Value: Missing | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 |
| Urea Nitrogen — Cohort B - Baseline Value: Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants | High Risk Prostate Cancer (Cohort A) - Baseline ECG | High Risk Prostate Cancer (Cohort A) - Post-dosing ECG | Recurrent or Metastatic Prostate Cancer (Cohort B) - Baseline ECG | Recurrent or Metastatic Prostate Cancer (Cohort B) - Post-dosing ECG |
|---|---|---|---|---|
| Normal ECG Evaluation | 159 | 155 | 55 | 51 |
| Abnormal ECG Evaluation | 101 | 109 | 59 | 64 |
| mm Hg | High Risk Prostate Cancer (Cohort A) | Recurrent or Metastatic Prostate Cancer (Cohort B) |
|---|---|---|
| Systolic Blood Pressure: Baseline (Actual) | 133.7 ± 15.99 | 133.6 ± 19.00 |
| Systolic Blood Pressure: Post-dosing (Actual) | 133.7 ± 16.57 | 132.1 ± 19.11 |
| Systolic Blood Pressure: Change from Baseline | 0.1 ± 12.30 | -1.3 ± 11.57 |
| Diastolic Blood Pressure: Baseline (Actual) | 79.3 ± 8.62 | 77.2 ± 10.16 |
| Diastolic Blood Pressure: Post-dosing (Actual) | 78.5 ± 9.12 | 76.4 ± 9.02 |
| Diastolic Blood Pressure: Change from Baseline | -0.7 ± 7.04 | -0.7 ± 8.18 |
| beats per minute | High Risk Prostate Cancer (Cohort A) | Recurrent or Metastatic Prostate Cancer (Cohort B) |
|---|---|---|
| Heart Rate: Baseline (Actual) | 70.7 ± 12.03 | 71.3 ± 12.94 |
| Heart Rate: Post-dosing (Actual) | 66.4 ± 10.98 | 67.0 ± 11.23 |
| Heart Rate: Change from Baseline | -4.4 ± 6.88 | -4.6 ± 6.53 |
| breaths per minute | High Risk Prostate Cancer (Cohort A) | Recurrent or Metastatic Prostate Cancer (Cohort B) |
|---|---|---|
| Respiration Rate: Baseline (Actual) | 16.7 ± 3.33 | 17.3 ± 2.16 |
| Respiration Rate: Post-dosing (Actual) | 16.6 ± 3.32 | 17.3 ± 2.28 |
| Respiration Rate: Change from Baseline | -0.1 ± 2.03 | 0.0 ± 2.00 |
| degrees Celsius | High Risk Prostate Cancer (Cohort A) | Recurrent or Metastatic Prostate Cancer (Cohort B) |
|---|---|---|
| Temperature: Baseline (Actual) | 36.58 ± 0.433 | 36.56 ± 0.338 |
| Temperature: Post-dosing (Actual) | 36.50 ± 0.479 | 36.59 ± 0.309 |
| Temperature: Change from Baseline | -0.08 ± 0.496 | 0.03 ± 0.265 |
Sensitivity (True Positive rate) measures the proportion of positives that are correctly identified (i.e., the proportion of those who have some condition (affected) who are correctly identified as having the condition).
| percentage of participants | Recurrent or Metastatic Prostate Cancer (Cohort B) |
|---|---|
| Central Reader 1 | 98.6 (91.60 to 100.00) |
| Central Reader 2 | 95.8 (87.81 to 99.04) |
| Central Reader 3 | 92.9 (83.98 to 97.28) |
The number of lesions detected on imaging categorized as bone, visceral/soft tissue, lymph nodes, and the prostate gland will be determined by each of the central imaging core lab independent readers. The sum of lesions per participant per tissue type and overall will be computed for each participant based on each reader's lesion count. This will be calculated from the 18F-DCFPyL PET/CT scan results as well as the conventional imaging results.
| Participants | Cohort A - Conventional Imaging | Cohort A - 18F-DCFPyL PET/CT: Reader 1 | Cohort A - 18F-DCFPyL PET/CT: Reader 2 | Cohort A - 18F-DCFPyL PET/CT: Reader 3 | Cohort B - Conventional Imaging | Cohort B - 18F-DCFPyL PET/CT: Reader 1 | Cohort B - 18F-DCFPyL PET/CT: Reader 2 | Cohort B - 18F-DCFPyL PET/CT: Reader 3 |
|---|---|---|---|---|---|---|---|---|
| Tissue Site: Bone — Number of Lesions: 0 | 239 | 234 | 247 | 237 | 37 | 22 | 28 | 23 |
| Tissue Site: Bone — Number of Lesions: 1-2 | 9 | 17 | 4 | 13 | 20 | 21 | 24 | 22 |
| Tissue Site: Bone — Number of Lesions: 3-4 | 0 | 1 | 1 | 2 | 8 | 10 | 4 | 10 |
| Tissue Site: Bone — Number of Lesions: 5-6 | 2 | 0 | 0 | 0 | 1 | 3 | 5 | 2 |
| Tissue Site: Bone — Number of Lesions: >6 | 1 | 0 | 0 | 0 | 26 | 37 | 32 | 36 |
| Tissue Site: Visceral/Soft Tissue — Number of Lesions: 0 | 233 | 241 | 249 | 240 | 72 | 71 | 73 | 64 |
| Tissue Site: Visceral/Soft Tissue — Number of Lesions: 1-2 | 16 | 11 | 3 | 12 | 13 | 15 | 14 | 20 |
| Tissue Site: Visceral/Soft Tissue — Number of Lesions: 3-4 | 1 | 0 | 0 | 0 | 3 | 2 | 1 | 4 |
| Tissue Site: Visceral/Soft Tissue — Number of Lesions: 5-6 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 0 |
| Tissue Site: Visceral/Soft Tissue — Number of Lesions: >6 | 1 | 0 | 0 | 0 | 2 | 4 | 3 | 5 |
| Tissue Site: Lymph Nodes — Number of Lesions: 0 | 157 | 216 | 226 | 218 | 37 | 38 | 37 | 38 |
| Tissue Site: Lymph Nodes — Number of Lesions: 1-2 | 39 | 28 | 19 | 25 | 18 | 11 | 16 | 10 |
| Tissue Site: Lymph Nodes — Number of Lesions: 3-4 | 10 | 5 | 4 | 5 | 8 | 7 | 13 | 10 |
| Tissue Site: Lymph Nodes — Number of Lesions: 5-6 | 16 | 3 | 3 | 3 | 7 | 8 | 4 | 8 |
| Tissue Site: Lymph Nodes — Number of Lesions: >6 | 29 | 0 | 0 | 1 | 22 | 29 | 23 | 27 |
| Tissue Site: Prostate Gland — Number of Lesions: 0 | 162 | 5 | 5 | 14 | 79 | 64 | 69 | 63 |
| Tissue Site: Prostate Gland — Number of Lesions: 1-2 | 88 | 199 | 209 | 204 | 12 | 20 | 22 | 30 |
| Tissue Site: Prostate Gland — Number of Lesions: 3-4 | 0 | 38 | 33 | 31 | 0 | 6 | 1 | 0 |
| Tissue Site: Prostate Gland — Number of Lesions: 5-6 | 0 | 10 | 4 | 3 | 0 | 1 | 0 | 0 |
| Tissue Site: Prostate Gland — Number of Lesions: >6 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 0 |
| Tissue Site: All — Number of Lesions: 0 | 109 | 3 | 5 | 14 | 14 | 3 | 11 | 7 |
| Tissue Site: All — Number of Lesions: 1-2 | 75 | 174 | 196 | 175 | 11 | 15 | 17 | 14 |
| Tissue Site: All — Number of Lesions: 3-4 | 16 | 55 | 38 | 47 | 8 | 10 | 9 | 8 |
| Tissue Site: All — Number of Lesions: 5-6 | 17 | 9 | 10 | 11 | 9 | 9 | 10 | 11 |
| Tissue Site: All — Number of Lesions: >6 | 35 | 11 | 3 | 5 | 50 | 56 | 46 | 53 |
Positive Predictive Value (PPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The PPV is determined from the number of true positives (positive 18F-DCFPyL image and a positive histopathology result for prostate cancer) divided by the number of participants with a positive 18F-DCFPyL image.
| percentage of participants | High Risk Prostate Cancer (Cohort A) |
|---|---|
| Central Reader 1 | 100.0 (98.1 to 100.0) |
| Central Reader 2 | 100.0 (98.1 to 100.0) |
| Central Reader 3 | 100.0 (98.1 to 100.0) |
Negative Predictive Value (NPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The NPV is determined from the number of true negatives (negative 18F-DCFPyL image and a negative histopathology result for prostate cancer) divided by the number of participants with a negative 18F-DCFPyL image.
| percentage of participants | High Risk Prostate Cancer (Cohort A) |
|---|---|
| Central Reader 1 | 0 (NA to NA) |
| Central Reader 2 | 0 (NA to NA) |
| Central Reader 3 | 0 (NA to NA) |
Positive Predictive Value (PPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The PPV is determined from the number of true positives (positive 18F-DCFPyL image and a positive histopathology result for prostate cancer) divided by the number of participants with a positive 18F-DCFPyL image.
| percentage of participants | High Risk Prostate Cancer (Cohort A) |
|---|---|
| Central Reader 1 | 86.7 (69.7 to 95.3) |
| Central Reader 2 | 90.5 (69.9 to 98.6) |
| Central Reader 3 | 78.1 (63.8 to 92.5) |
Negative Predictive Value (NPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The NPV is determined from the number of true negatives (negative 18F-DCFPyL image and a negative histopathology result for prostate cancer) divided by the number of participants with a negative 18F-DCFPyL image.
| percentage of participants | High Risk Prostate Cancer (Cohort A) |
|---|---|
| Central Reader 1 | 83.8 (78.9 to 88.6) |
| Central Reader 2 | 81.4 (76.4 to 86.4) |
| Central Reader 3 | 83.2 (78.2 to 88.1) |
Positive Predictive Value (PPV) is based on a 18F-DCFPyL PET/CT image result and a histopathology result. The PPV is determined from the number of true positives (positive 18F-DCFPyL image and a positive histopathology result for prostate cancer) divided by the number of participants with a positive 18F-DCFPyL PET/CT image.
| percentage of participants | Recurrent or Metastatic Prostate Cancer (Cohort B) |
|---|---|
| Central Reader 1 | 81.2 (72.9 to 89.5) |
| Central Reader 2 | 81.9 (73.7 to 90.2) |
| Central Reader 3 | 87.8 (80.4 to 95.3) |
| µCi/mL | Pharmacokinetic Subset of High Risk Prostate Cancer Participants (Cohort A) |
|---|---|
| Peak Plasma Concentration (Cmax) of 18F-DCFPyL in a Subset of Participants | 0.43 ± 0.088 |
| h*μCi/ml | Pharmacokinetic Subset of High Risk Prostate Cancer Participants (Cohort A) |
|---|---|
| Area Under the Plasma Concentration Versus Time Curve (AUC) of 18F-DCFPyL in a Subset of Participants | 0.82 ± 0.143 |
Collected over Treatment-emergent adverse events (TEAEs) were collected from Day 1 after 18F-DCFPyL administration through the day prior to prostatectomy, lymphadenectomy or a change in planned protocol procedure (Cohort A); if a participant did not have a procedure, TEAEs were collected for up to 10 days after 18F-DCFPyL administration. For participants in Cohort B, TEAEs were collected from Day 1 after 18F-DCFPyL administration through 28 days after biopsy.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| High Risk Prostate Cancer (Cohort A) | 0/268 (0%) | 1/268 (0.4%) | 26/268 (9.7%) |
| Recurrent or Metastatic Prostate Cancer (Cohort B) | 0/117 (0%) | 6/117 (5.1%) | 1/117 (0.9%) |
| Event | High Risk Prostate Cancer (Cohort A) | Recurrent or Metastatic Prostate Cancer (Cohort B) |
|---|---|---|
| coronary artery diseaseCardiac disorders | 1/268 | 1/117 |
| atrial fibrillationCardiac disorders | 0/268 | 1/117 |
| Lower gastrointestinal haemmorhageGastrointestinal disorders | 0/268 | 1/117 |
| pyelonephritis, acuteInfections and infestations | 0/268 | 1/117 |
| hyperkalaemiaMetabolism and nutrition disorders | 0/268 | 1/117 |
| spinal cord compressionNervous system disorders | 0/268 | 1/117 |
| Event | High Risk Prostate Cancer (Cohort A) | Recurrent or Metastatic Prostate Cancer (Cohort B) |
|---|---|---|
| dysgeusiaNervous system disorders | 9/268 | 1/117 |
| headacheNervous system disorders | 9/268 | 0/117 |
| fatigueGeneral disorders | 5/268 | 0/117 |
| diarrheaGastrointestinal disorders | 3/268 | 0/117 |
Safety population; total number of patients who received 18F-DCFPyL injection.
| Age, Continuous(years) | High Risk Prostate Cancer (Cohort A) | Recurrent or Metastatic Prostate Cancer (Cohort B) | Total |
|---|---|---|---|
| Median | 65 (46 to 84) | 68 (45 to 86) | 66 (45 to 86) |
| Sex: Female, Male(Participants) | High Risk Prostate Cancer (Cohort A) | Recurrent or Metastatic Prostate Cancer (Cohort B) | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 268 | 117 | 385 |
| Race/Ethnicity, Customized(Participants) | High Risk Prostate Cancer (Cohort A) | Recurrent or Metastatic Prostate Cancer (Cohort B) | Total |
|---|---|---|---|
| Race — White | 233 | 101 | 334 |
| Race — Black or African American | 23 | 6 | 29 |
| Race — Asian | 7 | 4 | 11 |
| Race — Other | 2 | 3 | 5 |
| Race — Unknown or Not Reported | 3 | 3 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Nov 2016 to primary completion in Jul 2018, 20 months.
Results were first posted in Aug 2021, 3 years 1 month after primary completion. A results delay was requested in Sep 2019.
Of 43 phase 2/3 interventional studies under Prostatic Neoplasms, half reached primary completion within 115 months of starting (the median), counting those still running; a quarter within 32. This study's 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Piflufolastat
Progenics Pharmaceuticals, Inc. →